via University of Pittsburgh School of Medicine
Cheap, Potent Pathway to Pandemic Therapeutics
By capitalizing on a convergence of chemical, biological and artificial intelligence advances, University of Pittsburgh School of Medicine scientists have developed an unusually fast and efficient method for discovering tiny antibody fragments with big potential for development into therapeutics against deadly diseases.
The technique, published today in the journal Cell Systems, is the same process the Pitt team used to extract tiny SARS-CoV-2 antibody fragments from llamas, which could become an inhalable COVID-19 treatment for humans. This approach has the potential to quickly identify multiple potent nanobodies that target different parts of a pathogen—thwarting variants.
“Most of the vaccines and treatments against SARS-CoV-2 target the spike protein, but if that part of the virus mutates, which we know it is, those vaccines and treatments may be less effective,” said senior author Yi Shi, Ph.D., assistant professor of cell biology at Pitt. “Our approach is an efficient way to develop therapeutic cocktails consisting of multiple nanobodies that can launch a multipronged attack to neutralize the pathogen.”
Shi and his team specialize in finding nanobodies—which are small, highly specific fragments of antibodies produced by llamas and other camelids. Nanobodies are particularly attractive for development into therapeutics because they are easy to produce and bioengineer. In addition, they feature high stability and solubility, and can be aerosolized and inhaled, rather than administered through intravenous infusion, like traditional antibodies.
By immunizing a llama with a piece of a pathogen, the animal’s immune system produces a plethora of mature nanobodies in about two months. Then it’s a matter of teasing out which nanobodies are best at neutralizing the pathogen—and most promising for development into therapies for humans.
That’s where Shi’s “high-throughput proteomics strategy” comes into play.
“Using this new technique, in a matter of days we’re typically able to identify tens of thousands of distinct, highly potent nanobodies from the immunized llama serum and survey them for certain characteristics, such as where they bind to the pathogen,” Shi said. “Prior to this approach, it has been extremely challenging to identify high-affinity nanobodies.”
After drawing a llama blood sample rich in mature nanobodies, the researchers isolate those nanobodies that bind specifically to the target of interest on the pathogen. The nanobodies are then broken down to release small “fingerprint” peptides that are unique to each nanobody. These fingerprint peptides are placed into a mass spectrometer, which is a machine that measures their mass. By knowing their mass, the scientists can figure out their amino acid sequence—the protein building blocks that determine the nanobody’s structure. Then, from the amino acids, the researchers can work backward to DNA—the directions for building more nanobodies.
Simultaneously, the amino acid sequence is uploaded to a computer outfitted with artificial intelligence software. By rapidly sifting through mountains of data, the program “learns” which nanobodies bind the tightest to the pathogen and where on the pathogen they bind. In the case of most of the currently available COVID-19 therapeutics, this is the spike protein, but recently it has become clear that some sites on the spike are prone to mutations that change its shape and allow for antibody “escape.” Shi’s approach can select for binding sites on the spike that are evolutionarily stable, and therefore less likely to allow new variants to slip past.
Finally, the directions for building the most potent and diverse nanobodies can then be fed into vats of bacterial cells, which act as mini factories, churning out orders of magnitude more nanobodies compared to the human cells required to produce traditional antibodies. Bacterial cells double in 10 minutes, effectively doubling the nanobodies with them, whereas human cells take 24 hours to do the same.
“This drastically reduces the cost of producing these therapeutics,” said Shi.
Shi and his team believe their technology could be beneficial for more than just developing therapeutics against COVID-19—or even the next pandemic.
“The possible uses of highly potent and specific nanobodies that can be identified quickly and inexpensively are tremendous,” said Shi. “We’re exploring their use in treating cancer and neurodegenerative diseases. Our technique could even be used in personalized medicine, developing specific treatments for mutated superbugs for which every other antibiotic has failed.”
Original Article: Cheap, Potent Pathway to Pandemic Therapeutics
More from: University of Pittsburgh School of Medicine | Carnegie Mellon University | Hebrew University of Jerusalem
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Pandemic therapeutics
- Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript
Q1 2024 Earnings Call May 8, 2024 Y-mAbs Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ...
- ASGCT 2024: Kate Therapeutics Unveils Gene Therapy Platform and Product Pipeline Progress
KateTx debuted less than a year ago with a $51 million Series A round co-led by Westlake Village BioPartners and Versant Ventures.
- Lisata’s Autologous T Cell Therapy is Safe but Fails to Slow T1D Disease Progression, Trial Finds
An autologous and personalized regulatory T cell therapy is safe in patients with type 1 diabetes, but does not help preserve β-cell function.
- Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
Crispr Therapeutics AG shows potential for future earnings with its gene editing therapy Casgevy, offering treatment for various diseases. Read more here.
- Zevra Therapeutics to Participate at Upcoming Investor Events
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will ...
Go deeper with Google Headlines on:
Pandemic therapeutics
[google_news title=”” keyword=”Pandemic therapeutics” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Therapeutic cocktails
- Sing-a-longs, crypto-shilling, and Ayahuasca: Ohio State’s commencement speech gone wrong
Chris Pan’s Ohio State University speech was a bizarre cocktail of sing-a-longs, crypto-shilling, and jewelry-slinging that left many in the audience stunned, Graig Graziosi reports.
- Microcurrent Pioneer Bio-Therapeutic Launches Professional Grade, Handheld Facial Sculpting Unit: the bt-sculpt®
Introducing the bt-sculpt®, a revolutionary facial toning unit created by Bio-Therapeutic, a family-owned legacy brand widely recognized as the leader in microcurrent technology. Designed to deliver ...
- Elderday Center hosts its spring fundraiser May 16
Elderday Center will host its 34th annual “Celebrating Dementia Champions” on Thursday, May 16. The spring fundraiser supports the dementia-friendly therapeutic adult day program. Through this ...
- Hartman's Distilling Co. attempts Guinness World Record for the largest mint julep cocktail
We're talking about a drink that's five feet tall and 207 gallons. A mint julep with 35 gallons of bourbon and 400 pounds of crushed ice.
- 41 Cocktails to Serve at Your Cinco de Mayo Celebration
Every item on this page was chosen by a Town & Country editor. We may earn commission on some of the items you choose to buy. While Cinco de Mayo may be a primarily American holiday, there's no ...
Go deeper with Google Headlines on:
Therapeutic cocktails
[google_news title=”” keyword=”therapeutic cocktails” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
[embedyt] https://www.youtube.com/embed?listType=playlist&list=PL0UjJ07OSXC83oV409r1yRju8-ihA1InJ&layout=gallery[/embedyt]